Trial Profile
Anti-TNF-Study Utilizing Biomarker Assay to Monitor Early Response to Certolizumab Pegol
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms TSUBAME
- 01 Jun 2021 Results assessing relation between serum TNFalpha levels and effectiveness of certolizumab-pegol published in the Arthritis Research and Therapy
- 12 Apr 2021 Status changed from active, no longer recruiting to completed.
- 06 Jun 2020 Primary endpoint (Change of DAS28-ESR at 12weeks) has been met according to the results presented at the 21st Annual Congress of the European League Against Rheumatism